CODX — Co-Diagnostics, Inc.

Nasdaq · Health Care · Health Care Equipment & Supplies · CIK 1692415 ·
Last close
$3.23
Market Cap
$11.81M
52W High
$13.54
52W Low
$1.26
ADV30
11,182,799
Next earnings
2026-08-14
Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. The company also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, malaria, dengue, human papillomavirus, chikungunya, and Zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. Co-Diagnostics, Inc. was incorporated in 2013 and is based in Salt Lake City, Utah.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 145,954 -47,814 -9,208,411 -9,140,038 21,499,726 8,230,984 5,457,316
Dec 2025 263,922 121,526 -7,659,784 -25,745,725 24,742,585 11,884,607 4,113,921
Sep 2025 145,380 119,095 -7,013,848 -5,886,823 44,740,761 11,443,943 4,912,516
Jun 2025 162,910 130,804 -8,057,764 -7,730,117 46,465,833 11,115,181 5,327,439

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-28,237,989
Investing CF
$18,774,432
Financing CF
$15,791,507
CapEx
$-750,151
Dividends Paid
Buybacks
$0
EPS Diluted TTM
$-22.96
As of
2026-06-07

Balance + Analyst (yfinance extras)

Retained Earnings
$-89,513,577
Inventory
$846,119
Receivables
$82,388
ST Investments
$0
EBIT TTM
$-31,939,807
Pretax Income TTM
$-50,130,165
Interest Exp TTM
Analysts

Yahoo Snapshot (yfinance, live)

Total Revenue
$718,166
EBITDA
$-30,858,000
Free Cash Flow
$-18,284,196
Enterprise Value
$5,435,332
Total Cash
$8,230,984
Total Debt
$2,030,354
Shares Out
3,657,380
Trailing EPS
$-32.26
Book Value
$4.45
ROE
-151.7%
ROA
-52.1%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 622,489 -31,283,352 -46,895,936 24,742,585 4,113,921 -29,136,927
Dec 2024 3,915,160 -40,081,310 -37,639,008 63,563,158 9,688,001 -29,155,045
Dec 2023 6,812,038 -42,706,234 -35,332,865 95,320,660 9,307,045 -22,081,865
Dec 2022 34,218,209 -11,591,291 -14,238,249 123,086,281 8,566,287 6,568,737

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$-12.00

Peers — same industry

TickerNameMarket CapLastDaily %
SINT Sintx Technologies, Inc. $11.91M $1.92
ALRTF ALR Technologies SG Ltd. $11.62M $0.02
FEMY FEMASYS INC $12.11M $4.01
OSRH OSR Health, Inc. $12.67M $0.36
MBAI Check-Cap Ltd $10.51M $1.36

News headlines (Yahoo Finance, 1h cache)

Co-Diagnostics Hosts Kingdom of Saudi Arabia Joint Venture CoMira for Unveiling of Future Automated Manufacturing Line
2026-06-18 13:00 · Yahoo
Co-Diagnostics Advances Latin American Commercialization Strategy for Co-Dx™ PCR Pro® with Mexico Distributor Agreement
2026-06-11 13:00 · Yahoo
Co-Diagnostics and CoSara Advance Ebola PCR Test Development and Co-Dx™ PCR Point-of-Care Platform Capabilities
2026-06-02 13:00 · Yahoo
Is Co-Diagnostics National Security’s Next Diagnostic Pick?
2026-05-28 15:00 · Yahoo
Co-Diagnostics (CODX) Q4 2025 Earnings Transcript
2026-05-27 20:52 · Yahoo
Top Midday Gainers
2026-05-26 17:54 · Yahoo
CODX Stock Explodes Over 630% In Six Sessions – Retail Traders Bet The Rally Isn’t Over Yet
2026-05-26 17:00 · Yahoo
Co-Diagnostics Advances Ebola PCR Assay Development Strategy with Joint Venture CoSara
2026-05-26 13:00 · Yahoo
Co-Diagnostics Announces $3.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules
2026-05-20 02:54 · Yahoo
Co-Diagnostics Develops Ebola Assay Strategy Following WHO Emergency Alert (CODX)
2026-05-19 14:34 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.